|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 13, 2020 ) The specimen validity testing market is expected to reach USD 1.86 billion by 2027 from USD 1.10 billion in 2018, at a CAGR of 6.3%. Growth in the drug & alcohol treatment and increase in workplace drug testing are the factors driving the growth of the specimen validity testing market.
Reagents, calibrators, and controls are expected to dominate the specimen validity testing products market in 2018.
Based on product, the specimen validity testing market is segmented into reagents, calibrators, and controls; assay kits; and disposables. In 2018, the reagents, calibrators, and controls segment is expected to dominate the market. The growth of this product segment is primarily attributed to the repeated purchase of these products.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=147024121
Based type, the rapid/POC testing segment is projected to grow at the highest CAGR during the forecast period.
Based on type, the specimen validity testing market is segmented into laboratory testing and rapid/POC testing. In 2018, the laboratory testing segment is expected to account for the largest share of the market. However, the rapid/POC testing segment is expected to register the highest CAGR during the forecast period. The high growth can be attributed to the instant results, detection of multiple drugs at once, and recurrent & repetitive usage of rapid/POC drug testing products.
North America to dominate the specimen validity testing market in 2018
In 2018, North America is expected to dominate the market followed by Europe. The large share of this region is attributed to factors such as growing consumption of illicit drugs, the presence of stringent laws mandating drug screening, availability of government funding (to help curb drug abuse), and the presence of key players in the region.
While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Intl, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
